BIO International Convention

Published: 21-May-2012

18 - 21 June 2012
Convention
Boston, MA, US

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, ceos, and celebrities

The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition - the BIO Exhibition.

Organiser: Biotechnology Industry Organization

Trending Articles

  1. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  2. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany
  3. Making Pharmaceuticals 23–24 April 2024 | Exhibition | Coventry, UK
  4. Interphex 16-18 April 2024 | Conference and Exhibition | New York, US
  5. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US

You may also like

Manufacturing

TiGenix expands manufacturing facility

TiGenix obtains commercial production licence for expanded manufacturing facility, to provide the capacity for potential European commercial roll out of investigational stem cell therapy, Cx601; the expansion also secures manufacturing for other pipeline products
Research & Development

TiGenix partners with US and EU patient advocacy groups focused on Crohn's disease and ulcerative colitis

Joins the Crohn's and Colitis Foundation's President's Corporate Circle
Research & Development

Takeda makes €10 million equity investment in TiGenix

Takeda Pharmaceuticals International AG will be subscribing 11,651,778 new ordinary shares at an issue price of €0.858 (rounded) per new share
Pharmaceutical

BIO 2016

6 - 9 June 2016, Event, Moscone Centre, San Francisco, CA, US
Finance

TiGenix to acquire Coretherapix for €6.7m

Expands its pipeline and enters the cardiology field with purchase of cell therapy company
Manufacturing

Lonza to manufacture Crohn's Disease treatment for TiGenix clinical trial in US

Cx601 product is currently in Phase III trials in Europe
Pharmaceutical

BIO 2015

15 - 18 June 2015, Convention, Philadelphia, PA, US
Subscribe now